MedTrace Logo

IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer

NCT05124795 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-01-17

No results posted yet for this study

Summary

Dose escalation study to evaluate the safety, tolerability and anti-tumor activity of single agent IMU-935 in patients with progressive, metastatic castration resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

IMU-935

IMU-935 capsules

Sponsors & Collaborators

  • Immunic AG

    lead INDUSTRY

Principal Investigators

  • J. B., MD · Institute of Cancer Research, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-09
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124795 on ClinicalTrials.gov